Site-specific antibody-drug conjugation through glycoengineering

US12110338B2 · kind B2 · utility

Assignee

• Genzyme Corporation · US

Inventors

• Clark Pan · Sudbury, US
• Qun Zhou · Ashland, US
• James Stefano · Bound Brook, US
• Pradeep K. Dhal · Westford, US
• Bo Chen · Jinan, CN
• Diego Gianolio · Somerville, US
• Robert J. Miller · Halifax, US
• Huawei Qiu · Westborough, US

Key dates

• Filing date: Aug 17, 2021
• Grant date: Oct 8, 2024
• Expiry date: Feb 1, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.